CRISPR screens of tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy

1. Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19⁺ B cell tumors: a phase 1/2 trial. Night. With. 30772–784 (2024). A recent clinical trial demonstrating the robust efficacy and superior safety of CAR-NK.

2. Vivier, E. et al. Natural killer cell therapies. Nature 626727–736 (2024). Comprehensive review discussing the current status of NK therapy.

3. Dong, M. B. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell 1781189–1204 (2019). This paper reports an early in vivo CRISPR screens in primary T cells.

   Article CAS PubMed PubMed Central Google Scholar

4. Ye, L. et al. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat. Biotechnol. 371302–1313 (2019). This paper demonstrates the application of an AAV-SB-CRISPR system in T cells.

   Article CAS PubMed PubMed Central Google Scholar

Download references

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Peng, L. et al. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02282-4 (2024).